About Cytochrome b
Cytochrome b (MT-CYB) is a protein
from Homo sapiens identified by UniProt accession
P00156, 380 residues long.
MolForge cross-references it against 0 known binders and
219 disease associations.
Target properties
| Protein name | Cytochrome b |
|---|
| UniProt accession | P00156 |
|---|
| Gene | MT-CYB |
|---|
| Organism | Homo sapiens |
|---|
| Length | 380 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (219)
Diseases linked to this target (Open Targets).
- Leber hereditary optic neuropathy · score 0.72
- Exercise intolerance · score 0.65
- mitochondrial disease · score 0.64
- MELAS · score 0.56
- MELAS syndrome · score 0.55
- mitochondrial myopathy with reversible cytochrome C oxidase deficiency · score 0.51
- mitochondrial encephalomyopathy · score 0.48
- histiocytoid cardiomyopathy · score 0.45
- maternally-inherited diabetes and deafness · score 0.45
- Mitochondrial myopathy · score 0.44
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P00156-F1 | alphafold | PREDICTED | 97.74 | — |
Amino-acid sequence (380 residues)
MTPMRKTNPL MKLINHSFID LPTPSNISAW WNFGSLLGAC LILQITTGLF LAMHYSPDAS TAFSSIAHIT RDVNYGWIIR YLHANGASMF FICLFLHIGR GLYYGSFLYS ETWNIGIILL LATMATAFMG YVLPWGQMSF WGATVITNLL SAIPYIGTDL VQWIWGGYSV DSPTLTRFFT FHFILPFIIA ALATLHLLFL HETGSNNPLG ITSHSDKITF HPYYTIKDAL GLLLFLLSLM TLTLFSPDLL GDPDNYTLAN PLNTPPHIKP EWYFLFAYTI LRSVPNKLGG VLALLLSILI LAMIPILHMS KQQSMMFRPL SQSLYWLLAA DLLILTWIGG QPVSYPFTII GQVASVLYFT TILILMPTIS LIENKMLKWA
Explore Cytochrome b with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets